Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Director departure
Appointed director

IVERIC bio, Inc. (OPHT) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/11/2023 8-K Resignation/termination of a director
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE SURVIVING CORPORATION",
"OFFICES"
07/06/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/01/2023 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other E...
Docs: "Agreement and Plan of Merger, by and among Astellas US Holding, Inc., Berry Merger Sub, Inc., IVERIC bio, Inc. and, solely as provided by Section ‎8.10(b) therein, Astellas Pharma Inc",
"Amendment to IVERIC bio, Inc.’s Amended and Restated Bylaws",
"Investor Contact:"
03/20/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
03/01/2023 8-K Quarterly results
01/06/2023 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
12/27/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
12/12/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
09/28/2022 8-K Investor presentation
Docs: "AVACINCAPTAD PEGOL IN GEOGRAPHIC ATROPHY DHAVAL DESAI SVP"
09/07/2022 8-K Other Events  Interactive Data
09/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Iveric Bio Announces Positive Topline Data from Zimura GATHER2 Phase 3 Clinical Trial in Geographic Atrophy"
07/26/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obl...
Docs: "Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results -Zimura® GATHER2 Topline Data Expected in September of this Year-"
07/05/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/04/2022 8-K Other Events  Interactive Data
03/25/2022 8-K Other Events  Interactive Data
02/24/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results –Zimura® GATHER2 Topline Data Expected in the Second Half of 2022 -"
01/11/2022 8-K Appointed a new director
Docs: "AMENDMENT NO. 3 TO NON-EMPLOYEE DIRECTOR COMPENSATION POLICY  OF IVERIC BIO, INC."
01/11/2022 8-K Other Events  Interactive Data
11/09/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Iveric Bio Reports Third Quarter 2021 Operational Highlights and Financial Results –Zimura® GATHER2 Enrollment Complete&#59; Retention Exceeding Expectations, with Injection Fidelity Rate Target of Greater than 90% -"
10/25/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "9,000,000 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT",
"Letter re: IVERIC bio, Inc. - Registration Statement on Form S-3",
"Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock , October 21, 2021 – IVERIC bio, Inc. , today announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $150.8 million, before underwriting discounts and commissions and offering expenses payable by the Comp..."
10/21/2021 8-K Other Events  Interactive Data
10/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/04/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results –FDA Agreement Under Special Protocol Assessment Received for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration –"
07/14/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "11,650,000 Shares IVERIC BIO, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT",
"Letter re: IVERIC bio., Inc. - Registration Statement on Form S-3",
"IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock , July 12, 2021 – IVERIC bio, Inc. , today announced the pricing of an underwritten public offering of 11,650,000 shares of its common stock at a price to the public of $8.60 per share, less underwriting discounts and commissions. In addition, in connection with the offering, the Company has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,747,500 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by the Company. The gross proceeds from the offering are expected to be approximately $100.2 million, before underwriting discounts and commissions and offering expenses payable by the Comp..."
07/12/2021 8-K Other Events  Interactive Data
07/06/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy